Adrenal incidentalomas are tumors that are serendipitously found by radiological examination. The incidence of adrenal incidentalomas in patients undergoing abdominal CT approaches 1%. The evaluation of a patient with an adrenal incidentaloma requires, in addition to a clinical history and physical examination, a focused biochemical evaluation to investigate if there is excess secretion of catecholamines, glucocorticoids, or aldosterone. Some tumors have specific features on imaging that identify them as benign or malignant. The recommendations for management of adrenal incidentalomas include resection of all functioning tumors regardless of size, preferably by the laparoscopic approach. Large, non-functional tumors should also be removed. Biochemical and radiological surveillance is recommended for at least one year, if a tumor is left in place.
INTRODUCTION
Adrenal incidentalomas are tumors that are serendipitously found by radiological examination of patients who have no symptoms or clinical findings suggestive of adrenal disease. These tumors are clinically important, since some may be malignant and others may produce excessive amounts of hormone. The functional adrenal incidentalomas consist of pheochromocytomas, aldosteronomas and cortisol-producing cortical adenomas; all of these may be associated with morbidity if untreated. Symptomatic patients and patients undergoing diagnostic imaging for a suspected or confirmed malignancy do not, by definition, have an incidentaloma (1).
Adrenal incidentalomas seem to be related to age. Autopsy studies have shown that the frequency in patients younger than 30 years is less than 1%, in persons older than 50 years 3 %, and in patients 70 years or older approximately 7 %. There is no difference in sex distribution.
The incidence of adrenal incidentalomas in patients undergoing abdominal CT is about 1%. The incidentalomas are usually small, 1 to 2 cm at diagnosis. Recent reports suggest that up to 20 % of patients with adrenal incidentalomas have some form of subclinical hormonal dysfunction and that they may represent a population at an enhanced risk of metabolic disorders and cardiovascular disease (2). The risk of malignancy in the general population is about one in every 4000 tumors (3). In patients with a history of cancer, on the other hand, the frequency of asymptomatic adrenal tumors approaches 5%; almost 50 % are metastases. The most common tumors that metastasize to the adrenals are melanoma, renal cell carcinoma, and lung, breast and colon cancer (4).
The clinical indication for CT in patients who turn out to have an adrenal incidentaloma varies. The indication may be nonspecific abdominal pain (29 %), follow up evaluation of a non-adrenal intra-abdominal condition (21 %), hepatocholecystopathy (12 %), follow up of abdominal surgery (11 %), lumbar pain (7 %) and nephropathy (5 %) (3).
The evaluation of a patient who is found to have an adrenal tumor requires a complete history and physical examination, a focused biochemical evaluation, and, often, additional radiological studies. The clinical and biochemical workup is designed to determine whether the patient excretes an excess of catecholamines, glucocorticoids, aldosterone or virilizing hormones and whether the tumor is malignant.
Forty per cent of the pheochromocytomas are incidentalomas or give only mild clinical manifestations. The sensitivity of increased urinary or plasma free metanephrines (normetanephrine and metanephrine) for identifying a medullary tumor (pheochromocytoma) is 99 % and the specificity is 89 %. Most authors agree that the measurement of urinary metanephrines is the most useful screening test.
An adrenal cortical tumor that causes mild or subclinical Cushing's syndrome may be benign (adenoma) or malignant (carcinoma). Adrenal cortical carcinomas tend to be larger at the time of identification than adenomas and are more likely to secrete several other hormones in addition to cortisol, including estradiol or testosterone, dehydroepiandrosterone (DHEAS), and androstenedione (5). Patients with subclinical Cushing's syndrome are at risk of developing overt Cushing's syndrome and have several metabolic abnormalities that can be treated by adrenalectomy. Unfortunately, this subclinical syndrome has not been fully characterized, and its natural history is unknown. The supreme test for screening for subclinical hypercortisolism is the 1 mg dexamethasone suppression test. A traditional cutoff value is set at 140 nmol/L (2).
The aldosteronomas tend to be small (less than 2 cm) and cause severe and poorly controlled hypertension (4). If the patients do not have hypertension, autonomous aldosterone production is suggested by hypokalemia, an increased ratio of plasma aldosterone vs plasma renin activity and an increased plasma concentration are highly suggestive of autonomous aldosterone production (2).
Virilizing and feminizing adrenal tumors are rare (6). Benign adrenocortical tumors rarely secrete sex hormones (7), and less than half of the adrenal carcinomas raise the concentration of DHEAS, which has been considered as a marker of malignancy. The sensitivity of a raised DHEAS concentration for malignancy has a sensitivity of only 17 % but a specificity of 93 % (8,9 ). Since all virilizing and feminizing tumors are symptomatic, screening for androgen or estrogen excess in patients with an adrenal incidentaloma is, in fact, unnecessary (10) .
Some adrenal tumors, such as the myelolipomas and cysts, have specific features that allow an accurate diagnosis by imaging. The myelolipomas are benign neoplasms of the adrenal cortex composed of a mix of mature adipose cells and hemopoietic tissue. Although most tumors are hormonally inactive, isolated cases of hyperfunction have been reported. The fatty component of the myelolipomas gives the tumor properties that generate low density inhomogeneous images virtually diagnostic of the disease. By MRI, the fatty component appears as areas of enhanced intensity on T1-weighted images and inter-mediate on T2-weighted images. Asymptomatic adrenal myelolipomas can be treated conservatively, as the risk of hemorrhage or tumor progression is low. If they increase in size and cause local symptoms resection may be indicated.
Adrenal cysts are rare. They are usually unilateral and more common among females than males. Endothelial cysts are the most common type and account for 45 % of all adrenal cysts. Epithelial and parasitic cysts are uncommon. Pseudocysts which probably relate to adrenal hemorrhage constitute 40 % of the adrenal cysts.
On CT, the cysts are seen as a smooth, round, lowdensity mass with thin walls, while the appearance on MRI may be more variable. On MRI, a cyst may appear as a simple round mass that is homogeneously hypointense on T1-weighted and hyperintense on T2-weighted images, but also as a more complex tumor with a soft tissue component, nodularity, septation or hemorrhage and such an appearance may need to be differentiated from malignant neoplasms. Complicated cysts may require surgical resection, especially if there is a suspicion of malignancy.
Adrenal hemorrhage may be spontaneous, traumatic or related to anticoagulation. Hemorrhage appears on CT as a unilateral or bilateral hyperdense mass, which during follow up gradually decreases in size and density. The MRI findings of adrenal hemorrhage reflect the evolution from acute to chronic disease stages in pace with hemoglobin breakdown. In the acute phase deoxyhemoglobin causes typically signal loss on T1-weighted and T2-weighted images, and in the subacute phase methemoglobin leads to high signal intensity on T1-weighted images, whereas in the chronic phase the signal intensity on T1-weighted and T2-weighted images is low due to calcification and hemosiderin deposition. On sonography adrenal hemorrhage appears as an anechoic mass that may displace or compress the upper pole of the kidney (3).
Magnetic resonance imaging CT can be of some help in distinguishing benign from malignant lesions. A homogeneous mass with a smooth border and an attenuation value of less than 10 HU on unenhanced CT strongly suggests a benign adrenal adenoma. Benign adenomas also exhibit a signal drop on chemical-shift imaging and have an intensity similar to that of the liver on T2-weighted images (2).
Special imaging procedures, such as positron emission tomography, radionuclide scintigraphy with iodocholesterol and 131 I metaiodobenzyl guanidine are not widely available, and data on their clinical usefulness is still insufficient (4, 11).
Fine needle aspiration biopsy has a limited role, but it is a useful procedure to diagnose adrenal metastasis (12) . The overall accuracy of CT-guided fine needle aspiration biopsy is 90 %, but in as much as 20 % of the times the material is insufficient for diagnosis (8). Complications such as abdominal pain, hematuria, pancreatitis, pneumothorax, bleeding, and abscess formation are rare. Fine needle aspiration should be avoided if pheochromocytoma or echinococcal parasitic cyst are suspected, since the procedure can be harmful (13) .
MANAGEMENT OF ADRENAL INCIDENTALOMAS
The recommendations for the treatment of adrenal incidentalomas range from excision regardless of the size and the endocrine activity of the tumor to extensive hormonal and morphological evaluation before considering surgery. For hyperfunctioning masses there is general agreement that aldosteronomas and pheochromocytomas, although clinically silent, should be excised, while the appropriate management for nonclinical hypercortisolism is still a matter of debate. Since patients with subclinical Cushing's syndrome may develop arterial hypertension, obesity, diabetes mellitus or impaired glucose tolerance, and osteoporosis, surgical treatment is often a reasonable choice. For practical purposes, all hormone-secreting cortical and medullar tumors should be resected regardless of the likelihood of malignancy (14, 15) .
For non-functioning tumors size has been considered the best guide to determine the need for resection, since there are no effective methods for differential diagnosis and since carcinomas tend to be larger than adenomas (2). Different authorities propose a different size threshold for resection; it has been set as low as 2-3 cm and as high as 5-6 cm. Although adrenocortical cancers are likely to be larger than 6cm, the number of reported small adrenal cortical carcinomas is growing. Lesions smaller than 3 cm can be safely observed unless there is a clear suspicion of malignancy, while tumors greater than 6 cm are more likely to be malignant and should be resected.
The optimal management of adrenal masses between 4 and 6 cm has not been established. Older patients are more likely to have non-secreting adenomas than younger patients and it might be appropriate to adapt the resection threshold by age and presence of other illnesses (4).
Laparoscopic adrenalectomy has emerged as the treatment of choice of benign functioning and nonfunctioning adrenalopathy (14) (15) . Laparoscopic adrenalectomy is effective and safe and, when compared with open adrenalectomy, laparoscopic adrenalectomy is associated with a shorter hospital stay, need for less analgesics, faster convalescence, less operative blood loss, rapid reconstitution of dietary intake, superior cosmesis, and a lower rate of postoperative complications, like bleeding, wound infection, subcutaneous emphysema, and pancreatic or splenic injury (14) (15) (16) (17) (18) (19) (20) (21) .
Whether laparoscopic adrenalectomy is the best treatment of potentially malignant primary adrenal tumors or adrenal metastasis is controversial (22) (23) (24) . Open adrenalectomy seems more appropriate for tumors with obvious local invasion, or when lymphadenectomy or resection of adjacent organs is required (4). Some large, invasive adrenal tumors may require a thoracoabdominal incision, but most tumors can be resected through an anterior or lateral abdominal incision (25) . Regardless of whether the adrenalectomy is performed open or laparoscopically, the adrenal gland must be resected in toto, and the tumor capsule must not be broken (4).
If open adrenalectomy were chosen as the treatment for all patients with adrenal incidentalomas who need surgery on the base of tumor size, too many patients would undergo an unnecessary open procedure. At our institution we would favor to start the operation laparoscopically if the tumor is relatively small and obvious local invasion is not seen, and it is probable that the operation can be safely completed laparoscopically. In the presence of local invasion the operation can be converted to a hand-assisted technique or to an open procedure. We believe a laparoscopic approach is reasonable also for malignant adrenal neoplasm when a complete resection is technically feasible and if there is no evidence of local invasion. In addition to a meticulous surgical technique, a nonpermeable retrieval bag must be used (25) .
Follow up of patients with non-functioning adrenal masses suggests that 5%-25 % of masses increase in size by at least 1 cm. The risk of malignancy is about 1 out of 1000. Up to 20 % of patients develop hormone overproduction. Tumors 3 cm or more in diameter are more likely to become hyperfunctional than smaller tumors (3). In order to evaluate changes in function and tumor size, follow up at 6 months and 12 months is warranted (2).
In summary, the recommendations for the evaluation and management of adrenal incidentalomas include: monitored periodically for size change and emergent hyperfunction, initially at 6 months and subsequently at 12 months' intervals. 5. Needle biopsy is rarely indicated and can be dangerous. It rarely distinguishes adrenal cortical carcinoma from adrenal cortical adenoma and can cause tumor seeding. Hemorrhage and hyperten-sive crisis are life-threatening complications of needle biopsing in patients with pheocromocytoma. Still, fine-needle aspiration cytology may be useful when metastasis is the likely diagnosis and adrenal resection is not planned or when a nonadrenal tumor, such as retroperitoneal lymphoma or sarcoma, is suspected. 6. In patients who have an obvious need for resection hormonal studies to rule out pheochromocytoma and subclinical Cushing's syndrome must still be performed. Appropriate perioperative endocrine preparation ( α -adrenergic blockade to prevent hypertensive crisis or steroid replacement to prevent addisonian crisis) is crucial for these patients (26) .
